Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hebuterne, X.
215  Ergebnisse:
Personensuche X
?
1

P679 Anti-TNF de-escalation following a treat-to-target str..:

Vuitton, L ; Poullenot, F ; Bouhnik, Y...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1290-i1290 , 2024
Link: https://doi.org/10.1093/..
 
?
2

P903 Persistence, efficacy and tolerance of subcutaneous In..:

Mathieu, N ; Heluwaert, F ; Riviere, P...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1655-i1655 , 2024
Link: https://doi.org/10.1093/..
 
?
3

P900 A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIA..:

Carbonnel, F ; Barnich, N ; Hébuterne, X...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1650-i1650 , 2024
Link: https://doi.org/10.1093/..
 
?
4

Risk of anti-TNF therapy on pregnancy, breastfeeding, live ..:

Bendaoud, S. ; Nahon, S. ; Beaugerie, L....
Digestive and Liver Disease.  , 2024
Link: https://doi.org/10.1016/..
 
?
5

N10 Evaluation of the impact of an IBD nurse in an Inflamma..:

Rachart, A ; Cluzeau, V ; Martins, C..
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i2210-i2211 , 2024
Link: https://doi.org/10.1093/..
 
?
6

Infliximab is an effective option in patients with ulcerati..:

Hupé, M. ; Streichenberger, A. ; Wils, P....
Digestive and Liver Disease.  , 2024
Link: https://doi.org/10.1016/..
 
?
7

P927 Long-term outcomes of risankizumab in Crohn's disease:..:

Fumery, M ; Caron, B ; Hébuterne, X...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1686-i1686 , 2024
Link: https://doi.org/10.1093/..
 
?
8

P404 Persistence of subcutaneous infliximab after switching..:

Mathieu, N ; Riviere, P ; Heluwaert, F...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i533-i534 , 2023
Link: https://doi.org/10.1093/..
 
?
9

P638 Effectiveness and safety of risankizumab induction the..:

Fumery, M ; Defrance, A ; Roblin, X...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i770-i770 , 2023
Link: https://doi.org/10.1093/..
 
?
10

DOP89 Impact of biologics on the risk of early postoperativ..:

Fumery, M ; Nancey, S ; Nachury, M...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i166-i167 , 2023
Link: https://doi.org/10.1093/..
 
?
11

OP04 Efficacy of upadacitinib in ulcerative colitis: A phas..:

Vermeire, S ; Danese, S ; Hébuterne, X...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i8-i9 , 2023
Link: https://doi.org/10.1093/..
 
?
12

DOP36 Efficacy and safety of vedolizumab in patients with c..:

Sallette, M ; Bouhnik, Y ; Nachury, M...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i084-i085 , 2022
Link: https://doi.org/10.1093/..
 
?
13

DOP33 Role of adherent and invasive E. coli in Crohn's Dise..:

Buisson, A ; Sokol, H ; Hammoudi, N...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i082-i083 , 2022
Link: https://doi.org/10.1093/..
 
?
14

P465 Is golimumab serum level predictive of clinical remiss..:

Fumery, M ; Nancey, S ; Filippi, J...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i439-i439 , 2022
Link: https://doi.org/10.1093/..
 
?
15

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAP..:

Panaccione, R ; Danese, S ; Zhouwen, W...
Journal of the Canadian Association of Gastroenterology.  5 (2022)  Supplement_1 - p. 18-19 , 2022
Link: https://doi.org/10.1093/..
 
1-15